Light-chain (AL) amyloidosis is a form of plasma cell dyscrasias characterized by deposition of misfolded monoclonal immunoglobulin light chain-derived amyloid fibrils, resulting in abnormal dermatologic, musculoskeletal, connective tissue manifestations, and the progressive multi-organ dysfunction [1–4]. Previous study had shown that about 2–9 precursor diagnoses were made before the confirmation of AL amyloidosis, and the median time from the first precursor diagnoses to AL amyloidosis was nearly 3.2–21.4 months, indicating that the identification of AL amyloidosis poses difficulties [5].
